APEX1 and melanoma: The novel APE/Ref-1 inhibitor developed in our study (compound 2) showed promising anti-melanoma activities in vitro and in vivo, suggesting that targeting APE/Ref-1-mediated signaling might be a novel and effective strategy for melanoma therapy.